Loading
A phase 2 trial of Alisertib in HR-positive / HER2-negative breast cancer, run by Puma Biotechnology, Inc., now recruiting.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06369285 by Puma Biotechnology, Inc., with 225 participants planned, started 2024-11-19 and due to reach its primary completion in 2027-12-30. Interventions recorded: Alisertib and Endocrine therapy.
Shares Alisertib, Puma Biotechnology and the tag pipeline.
Shares Alisertib, Puma Biotechnology.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.